Inflammatix, Inc. is a molecular diagnostics company developing rapid tests designed to 'read' the immune system to improve disease diagnosis. A venture-backed startup and an Alumni of JLab San Francisco, the firm is building novel diagnostics for acute infections and sepsis based on unique immune biomarkers having identified and a capacity to monitor unique combinations of biomarkers present in infectious disease for rapid identification of those in need of emergency care prior to ICU admission. Current methods to diagnose acute infections are focus on finding the bug - and approach that is slow and relatively ineffective. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that affecetvely 'reads'? the immune system. The firm's HostDx tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. These results have been extensively validated and published in top-tier medical journals. In addition to the firm's direct-to-Phase II SBIR Award from DARPA, Inflammatix has a $6M BARDA award that could potential be 10-12 times that amount.